Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05481554
Other study ID # APHP211408
Secondary ID 2021-A02267-34
Status Not yet recruiting
Phase
First received
Last updated
Start date July 2022
Est. completion date December 2023

Study information

Verified date July 2022
Source Assistance Publique - Hôpitaux de Paris
Contact Jehane FADLALLAH, MD, PhD
Phone 01 42 49 45 83
Email jehane.fadlallah@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This aim of this study is the evaluation of the gut microbiota imbalance occurrence and its characterization in patients with common variable immunodeficiency associated to an enteropathy with or without porto-sinusoidal vascular disease.


Description:

Common variable immunodeficiency (CVID) is the most common symptomatic humoral deficiency in adults and is accompanied by digestive symptoms. It is associated with intestinal dysbiosis and half of the patients exert a clinical digestive disease, called enteropathy. Hepatic complications characterized by porto-sinusoidal vascular disease are observed in 10% of the CVID patients. This complication is associated with a high morbi-mortality. In our center experience and in the literature, clinical occurrence of enteropathy and hepatic disease are highly correlated. Considering (i) the anatomical link between the intestinal tractus and the portal circulation, (ii) the clinical correlation between enteropathy and the liver disease and (iii) the established relation between gut microbiota and alcoholic cirrhosis, we speculate that patients whom develop portosinusoidal complications exert a peculiar intestinal dysbiosis. This study could contribute to a better understanding of the hepatic disease development, hence allowing us to suggest novel therapies based on gut microbiota modification.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Patients with a common variable immunodeficiency according to immune deficiencies classification associated with : - enteropathy and porto-sinusoidal vascular disease - enteropathy without porto-sinuoidal vascular disease - Subject with health insurance (AME excepted) - Verbal agreement to participate at the study Exclusion Criteria: - Laxatives in the month preceding stool sample

Study Design


Intervention

Biological:
Stool sample
Only 1 stool sample will be collected during the patient hospitalisation scheduled within standard care.

Locations

Country Name City State
France Immunologie Clinique Hôpital Saint Louis Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of a dysbiosis Evaluate the occurrence of dysbiosis and characterize gut microbiota (function and composition) by genomic (16S) and metabolomic (short chain fatty acids, bile acids, tryptophan metabolites) analyses from stool samples of patients with a common variable immunodeficiency with only enteropathy compared to patients with common variable immunodeficiency with enteropathy and porto-sinusoidal vascular disease Day 7
Primary Characterization of gut microbiota Evaluate the occurrence of dysbiosis and characterize gut microbiota (function and composition) by genomic (16S) and metabolomic (short chain fatty acids, bile acids, tryptophan metabolites) analyses from stool samples of patients with a common variable immunodeficiency with only enteropathy compared to patients with common variable immunodeficiency with enteropathy and porto-sinusoidal vascular disease Day 7
Secondary Fecal calprotectin measurement Evaluate the contribution of fecal calprotectin measurement at diagnosis Day 7
See also
  Status Clinical Trial Phase
Recruiting NCT05971407 - The Effect of Chronic Remote Ischaemic Preconditioning on Blood Pressure in Older Adults N/A
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Recruiting NCT04390672 - Multivessel TALENT N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Completed NCT01684826 - X-ray Dose Reduction Study for Cardiac Angiography and Intervention N/A
Completed NCT01417910 - Predictors of Post Operative Outcome in Peripheral Vascular Surgical Patients N/A
Terminated NCT00935766 - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries Phase 3
Unknown status NCT01748383 - The Long-term and Short-term Efficacy and Safety of Transplantation Autologous Bone Marrow Cells (BMCs) in Patients With the First STEMI (ST Segment Elevation Myocardial Infarction) Phase 2
Recruiting NCT05907564 - Aventus Thrombectomy System Pulmonary Embolism Clinical Study N/A
Recruiting NCT03732612 - Inflammation in Vascular Disease
Completed NCT00000614 - Prevention of Recurrent Venous Thromboembolism (PREVENT) Phase 3
Completed NCT00000530 - Raynaud's Treatment Study (RTS) Phase 3
Completed NCT00000479 - Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer Phase 3
Completed NCT00000539 - Arterial Disease Multifactorial Intervention Trial (ADMIT) Phase 3
Completed NCT00000474 - Prevention and Treatment of Hypertension Study (PATHS) Phase 3
Completed NCT00000528 - Trials of Hypertension Prevention (TOHP) Phase 3
Completed NCT00000509 - Potassium and Sodium to Control Blood Pressure in Hypertensives Phase 3
Completed NCT00000501 - Hypertension Prevention Trial (HPT) Feasibility Study Phase 2
Completed NCT00000499 - Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) Phase 2